

Thank you for joining

The presentation will begin shortly







Rise to Immunize™ Monthly Webinar

Tdap 101

Lawrence Shulman, D.O., F.C.C.P., from ProHEALTH, Part of Optum





Today's Webinar

Campaign Updates

- Annual Survey
- Campaign Spotlight
- Resource of the Month
- Blinded Comparative Report
- Acclaim Award


Tdap 101


Featuring Lawrence Shulman, D.O., F.C.C.P.

Q&A Session









- Will be sent via email
- Will be available on website

(RiseToImmunize.org → "Resources" → "Webinars")



Ask questions during the webinar using the **Q&A feature**

 Questions will be answered at the end of the presentation

Annual Survey

Please complete by Friday, May 20th (tomorrow!)

MAY 2022									
Sun	Mon	Tue	Wed	Thu	Fri	Sat			
1	2	3	4	5	6	7			
8	9	10	11	12	13	14			
15	16	17	18	19	20	21			
22	23	24	25	26	27	28			
29	30	31	1	2	3	4			



2022 Survey

Thank you for completing the following Rise to Immunize™ survey. Your participation is essential in helping the campaign determine resources and support for 2022 and beyond. There are seven questions in the survey. Please note that survey results will be reported in aggregate only and no individuals or organizations will be identified.

* 1. What electronic health record (EHR) does your organization use? (If you have more than

one choose the primary one used for ambulatory care)

 ○ Epic ○ Cerner ○ Allscripts ○ Other (please specify) 2. Do you currently stratify your immunization data by patient demographics such as race, thnicity, age, insurance type?
 Allscripts Other (please specify) 2. Do you currently stratify your immunization data by patient demographics such as race,
Other (please specify) 2. Do you currently stratify your immunization data by patient demographics such as race,
Do you currently stratify your immunization data by patient demographics such as race,
○ No
○ No, but we are planning to
O I don't know
Yes (please specify what data you collect, e.g., flu by race)


Campaign Spotlight



Learn more about Janssen and our other campaign sponsors on the RIZE website under the "About" tab.

Resource of the Month









- The second Blinded Comparative Report will be available May 27
- Will be distributed via email
- Also available on the RIZE website
 - Under "Measurements" on the "Data Results" page

Flu Season (Measurement Year) ¹	Reporting Quarter ²	Report Due Date	Blinded Comparative Report Provided	
	Q3 2021	F-h 15 2022	Mar 29, 2022	
2021	Q4 2021	Feb 15, 2022		
2021	Q1 2022	Apr 15, 2022	May 27, 2022	
	Q2 2022	Jul 15, 2022	Aug 26, 2022	
	Q3 2022	Oct 14, 2022	Nov 29, 2022	
2022	Q4 2022	Jan 17, 2023	Feb 28, 2023	
2022	Q1 2023	Apr 14, 2023	May 26, 2023	
	Q2 2023	Jul 14, 2023	Aug 25, 2023	
	Q3 2023	Oct 16, 2023	Nov 29, 2023	
2022	Q4 2023	Jan 16, 2024	Feb 27, 2024	
2023	Q1 2024	Apr 15, 2024	May 29, 2024	
	Q2 2024	Jul 15, 2024	Aug 26, 2024	
T)	Q3 2024	Oct 15, 2024	Nov 26, 2024	
2024	Q4 2024	Jan 15, 2025	Feb 26, 2025	
2024	Q1 2025	Apr 15, 2025	May 28, 2025	
	Q2 2025	Jul 15, 2025	Aug 26, 2025	

AMGA'S Acclaim Award is Back!



Does your medical group embody the Quadruple Aim?

If so, consider applying for the 2023 Acclaim Award by submitting a one-page abstract detailing a recent effort your medical group underwent to align itself with the Quadruple Aim.

Call for abstracts begins: May 16, 2022

Abstracts due: June 24, 2022

To learn more and to submit an abstract, visit www.amga.org/acclaim





Innovation, Quality
& Leadership Conference

September 28-October 1, 2022 Grapevine, Texas amga.org/IQL22

Today's Speaker





Lawrence Shulman, D.O., F.C.C.P.

Chief Medical Officer; Pulmonary and Sleep Medicine Division Chief; and Medical Director for ProHEALTH's Sleep Center,
ProHEALTH, Part of Optum




Helping to Prevent the Preventable in Healthcare Systems—Pertussis Disease

AMGA Webinar, Dr. Lawrence Shulman

Outline

- Pertussis Disease Overview
- Economic Impact of Pertussis Transmission in Health Systems
- Improving Tdap Immunization Rates in Health Systems
- Key Takeaways






Pertussis Disease Overview

Pertussis: Highly Communicable Disease

- Acute respiratory infection caused by the Bordetella pertussis bacterium¹
- Highly contagious and spread directly from person to person through contact with airborne droplets¹
 - High reproductive number (R₀) of 15-17²
 - Compare with COVID-19 R₀ of 2–7³
- Incidence occurs in all ages, however it is reported as highest in infants⁴
 - In 2012 epidemic year⁵ more than 10,000 cases were reported in persons 20 years of age and older⁶





Severe Pertussis Infections Can Cause Complications in Adolescents and Adults

COMPLICATIONS¹

- Sinusitis
- Otitis media
- Pneumonia

- Weight loss
- Fainting
- Rib fracture

In a study that examined the effect of age on the clinical presentation of pertussis, complications were more frequent in adults compared to adolescents¹

Adults 28% vs Adolescents 16%

RIB FRACTURE FOLLOWING PERSISTENT COUGH AND CULTURE-CONFIRMED B. PERTUSSIS DISEASE IN A FEMALE PATIENT ²





Images from *The New England Journal of Medicine*. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.²


Rib fracture occurs in rare cases.1

Pertussis can be a Burden to Adolescents and Adults with Chronic Respiratory Comorbidities


ENHANCED PERTUSSIS SURVEILLANCE IN 7 US STATES^{1,2}

Among 15,942 pertussis cases reported, 515 patients were hospitalized²

Percentage of hospitalized pertussis patients compared to US average rates for asthma and COPD in adolescents (12-20, n=23)



Adolescents and adults with asthma are at an increased risk of pertussis and pertussis-related hospitalizations compared to individuals without asthma^{2,3}



 Adults with COPD are potentially at increased risk of pertussis diagnosis or pertussis-related hospitalizations compared to adults without COPD^{2,3}

COPD = chronic obstructive pulmonary disease

Pertussis: Underdiagnosed and Not Tested For

- Studies of prolonged cough illnesses in adults reveal that 13% to 20% are a result of B pertussis infection¹
 - Serologic studies suggest that the rate of B pertussis infection is 2.0% per year¹
- Can be overlooked, especially among adults²
 - Perception that pertussis is a childhood disease leads to frequent misdiagnoses of older age groups²
- Diagnosed by culture or polymerase chain reaction (PCR)³
- PCR has optimal sensitivity during the first 3 weeks of cough⁴

Chain Reaction (PCR) for Diagnosing Pertussis. https://www.cdc.gov/pertussis/clinical/diagnostic-testing/diagnosis-pcr-bestpractices.html.




Image from The New England Journal of Medicine. NEJM Procedure: Collection of Nasopharyngeal Specimens with the Swab Technique

Adult Immunization Rates Suboptimal in Comparison to Adolescents

ADOLESCENTS (AGES 13-17)

National Immunization Survey-Teen (2019)¹

Estimated Tdap vaccination coverage of US adolescents (n=18,788) in 2019:

90.2%

- More-established vaccination schedule
- School requirements in all 50 states²

ACIP recommendation for persons aged 13–17 years: These persons should receive a single dose of Tdap, preferably at a preventive care visit at age 11–12 years. To ensure continued protection against tetanus and diphtheria, 1 booster dose of either Td or Tdap should be administered every 10 years throughout life.⁴

ADULTS (AGES 19+)

National Health Interview Survey (2018)³

Estimated vaccination coverage of US adults (n=15,118) who in the past 10 years received Tdap:

31.2%

- Suboptimal coverage in adults
- Opportunity for vaccination

ACIP recommendation for persons aged ≥19 years: Regardless of the interval since their last tetanus or diphtheria toxoid—containing vaccine, persons aged ≥19 years who have never received a dose of Tdap should receive 1 dose of Tdap. To ensure continued protection against tetanus and diphtheria, booster doses of either Td or Tdap should be administered every 10 years throughout life.⁴

Tdap=tetanus, diphtheria, and acellular pertussis vaccine

References: 1. Elam-Evans LD, et al. MMWR. 2020;69:1109-1116. 2. Immunization Action Coalition https://www.immunize.org/laws/tdap.asp. Accessed April 19, 2021. 3. Lu P, Hung M, Srivastav A, et al. Surveillance of Vaccination Coverage Among Adult Populations — United States, 2018. MMWR Surveill Summ 2021;70(No. SS-3):1–26. 4. Havers FP, Moro PL, Hunter P, Hariri S, Bernstein H. Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019. MMWR Morb Mortal Wkly Rep 2020;69:77–83.

HCPs are at Increased Risk and are a Source of Pertussis Transmission

 HCP with unrecognized pertussis infection are a source of transmission to susceptible patients¹




- Pertussis has a prolonged incubation period and a long duration of nonspecific respiratory symptoms, which may delay diagnosis¹
- 1.7-fold greater risk for acquiring pertussis compared to the general population²



One method of preventing workplace pertussis transmission is through Tdap immunization³



Tdap Immunization Rates Among HCPs Remain Low, Despite an ACIP Recommendation in Place Since 2006¹



HCP=Health Care Provider

Occupational Exposure to Pertussis Occurs Across Health Care Settings

A CROSS-SECTIONAL STUDY FROM 2002 THROUGH 2011 FOUND THAT **219** PERTUSSIS CASES IN ONE PEDIATRIC CARE NETWORK LED TO **1193** CONFIRMED HCP EXPOSURES¹



71.1%


exposures occurred while the HCP was providing care for an index case* who presented with respiratory symptoms¹



77.5%

of exposures occurred in the Emergency Department (ED) and in ambulatory sites¹


^{*}An index case was defined as any patient who had a laboratory-confirmed diagnosis of pertussis that also resulted in an HCW exposure



Economic Impact of Pertussis Transmission in Health Systems

Annual Cost of Pertussis Disease Among Adults in the United States Is Significant

Analysis of the estimated annual human and economic burden of pertussis in the United States, 2013, among adults 50 to 64 years of age^{1,*}





^{*}Based on an estimated 180,568 annual pertussis disease cases among adults aged 50 to 64 years of age.

[†]Indirect (non-medical) costs were estimated by combining work-loss data with economic productivity data, including wages, fringe benefits/supplements, and household productivity.

Pertussis Disease in Adults with Chronic Respiratory Conditions Can be Even More Costly

Compared with matched patients, patients with pertussis and pre-existing COPD or asthma age^a accrued **greater all-cause^b adjusted costs** across study period¹





COPD = chronic obstructive pulmonary disease

P < 0.0001 for all differences

^a Patients aged ≥11 years with diagnosed pertussis and pre-existing COPD (n = 343) or asthma (n = 1041) were matched 1:1 to patients with diagnosed pertussis but without COPD or asthma.

^b All-cause health care costs included all medical and pharmacy costs, regardless of the corresponding diagnoses or prescriptions.

Pertussis Outbreaks in Health Care Facilities Incur Significant Costs

Examples of Outbreaks	Total Cost
2011: 15 cases of pertussis occurred among 10 health care professionals and 5 infants in an Arizona hospital ¹	\$97,745 ¹
 2004: 2 nosocomial outbreaks at a tertiary care hospital (A) and a pediatric hospital (B)² Hospital A reported that a 38-year-old emergency room physician was diagnosed with pertussis, and identified 738 persons (hospital staff, patients, and visitors) as potentially being exposed to the physician Hospital B reported that a 38-year-old respiratory therapist was presumed to have pertussis and identified 417 employees as potentially exposed 	(A): \$263,357 ² (B): \$121,130 ²
2003: 17 cases of pertussis occurred among HCP exposed to 1 infant for 1 day in a tertiary health care facility for pediatric and adult patients ³	\$74,870 ³

Types of Direct and Indirect Costs to a Hospital as a Result of a Pertussis Outbreak

Type of Cost and Activity	Resource Used	Unit Cost
<u>Direct costs</u>		
Molecular laboratory tests	PCR test	\$286
Culture laboratory tests	Culture tests ^a	\$17
Treatment and prophylaxis	Azithromycin courses	\$35
 Additional activities^b Identification of cases and contacts Pertussis related counseling Conducting of laboratory tests Management of a telephone hotline for community inquires 	Labor hours	\$11-\$124
Information dissemination	Letters	\$0.6-\$4
<u>Indirect costs</u>		
HCWs' furlough ^c	Administrative-leave hours	\$20

a Culture tests of nasopharyngeal secretions.

b Additional activities included, but were not limited to, identification of cases and contacts, pertussis-related counseling, conducting of laboratory tests, and management of a telephone hotline for community inquires. c A total of 17 health care workers (HCWs) were placed on administrative leave; an average hourly earnings estimate of \$20/h was used.

Healthcare Worker Vaccination Program Implementation Results in Savings

IN A 10-YEAR PERIOD, THE VALUE OF COSTS ASSOCIATED WITH 1:

Containment Activities:

~\$388,000

• 0 •



Vaccination Program:

~\$69,000

- Introduction of a healthcare worker^b vaccination program could result in a net savings as high as \$535,000 and a benefit-cost ratio of 2.38 for a hospital with 1,000 HCWs¹
 - For every dollar spent on the vaccination program, the hospital would save \$2.38 on control measures¹

^a Costs were determined by interviewing infection-control and hospital personnel, reviewing billing records, and surveying symptomatic HCW. Benefits and costs of a vaccination program for HCWs was calculated using a probabilistic model to estimate the number of pertussis exposures that would require control measures annually

^B A stable cohort of 1000 HCWs is followed for 10 years, both with and without a pertussis vaccination program Limitation: model may not have accounted for cost of booster doses, program acceptance, hospital organizational culture.



Improving Tdap Immunization Rates in Health Systems

Healthy People 2030 Goals

HEALTHY PEOPLE 2030 SETS DATA-DRIVEN NATIONAL OBJECTIVES TO IMPROVE HEALTH AND WELL-BEING OVER THE NEXT DECADE 1



Reduce cases of pertussis among infants (IID-05: baseline only)²



Image from Office of Disease Prevention and Health Promotion



Increase the proportion of adults age 19 years or older who get recommended vaccines (IID-D03: in development status)²



Increase the proportion of pregnant women who receive 1 dose of the tetanus-diphtheria-acellular pertussis (Tdap) vaccine during pregnancy (IID-D01: in development status)²

Recommended Strategies to Increase Vaccine Coverage

FOR EMPLOYEES

- Consider the level of vaccination coverage among HCP to be one measure of patient safety and quality¹
- Implement **employee health clinics** for Tdap immunization¹
- Measure employee immunization rates and compare data to a desired target¹
- Provide vaccinations to employees at minimal or no cost¹
- Create a **task force** to communicate with individual staff members to champion Tdap immunization²


FOR PATIENTS

- Utilize education materials such as posters, pamphlets, brochures⁴
- Vaccination opportunities at the time of physical examinations or sick visits for minor illness or injury⁴
- If vaccination is deferred because of more serious illness, vaccinate as soon as the acute illness has improved⁴
- Use reminder-recall systems, standing orders and immunization information systems³
- Recommend **simultaneous vaccination** if timing aligns (eg, offer other vaccines at the time of influenza vaccination)⁴

Help Increase Tdap Vaccination Rates in Adults by Utilizing Emergency Care Settings



- Emergency care plays a significant role in healthcare delivery and is utilized as an access point for primary care¹
- In a CDC study, ~80% of ER visits by adults were due to lack of access to other providers²



As per NHIS 2017 data, Tdap vaccination coverage among adults is ~32%³



ER visits can be utilized as opportunities for Tdap immunization in eligible patients

Multiple Approaches to Reduce Costs while Implementing Vaccination Strategies



Avoiding errors in coding and billing¹

- Remember to bill for both the vaccine and vaccine administration
- Review vaccine manufacturer billing and coding guides
- Consider 2021 E&M Codes for information on billing for vaccine counseling



Routinely updating drop-down menus and other electronic health record tools¹

Preventing errors improves patient care and reduces claims rejections



Many vaccine manufacturers offer vaccine return programs to decrease the risk of losing money from expired vaccines¹



Improving efficiency of vaccination implementation and vaccine delivery can reduce the fixed costs per vaccine administered¹



Quality measures can be tied to insurance payment¹

HEDIS Quality Measures Related to Tdap Immunization



Endorsed by NCQA in 2019

Adult Immunization Status: the percentage of members 19 years of age and older who are up to date on recommended routine vaccines for influenza, Td or Tdap, zoster, and pneumococcal¹



Endorsed by NCQA in 2019

<u>Pregnancy Immunization Status:</u> The percentage of deliveries in the measurement period in which women received influenza and **tetanus**, **diphtheria toxoids and acellular pertussis (Tdap) vaccinations**¹

HEDIS=Healthcare Effectiveness Data and Information Set; NCQA=National Committee for Quality Assurance Td=tetanus and diphtheria toxoids adsorbed Tdap=tetanus, diphtheria, and acellular pertussis

Strategies for Improving Tdap Vaccination Rates in Health Care Settings are Shown to Increase Coverage

MANDATED MEASURES¹

Mandatory Tdap Employee Vaccination Program:

2009-2011; n=15,267

- High-risk areas: inpatient and outpatient areas of women's health, pediatrics, emergency department
- All clinical campuses and buildings

Vaccination coverage increased from:

9% to 90%

Geisinger Health System (Danville, PA)

QUALITY IMPROVEMENT INITIATIVE²

Improvement Effort Included:

2014-2017; n=1,090

- Changes to Occupational Health Program processes
- Education campaign
- Improved access to vaccine
- Personal engagement of HCP by task force members

Vaccination coverage increased from:

58% to 90%

St. Jude Children's Research Hospital (Memphis, TN)

Key Takeaways















• Many strategies to help increase vaccination rates for both healthcare providers and patients can be implemented in your healthcare facility

Selected Strategies From the 4 Pillars[™] Practice Transformation Program to Improve Vaccination Uptake¹

- 1 Provide convenience and easy access
- Use every patient visit type as an opportunity to vaccinate
- Offer other vaccines at the time of influenza vaccination if timing aligns
- Extend the influenza vaccination season
 - Vaccinate as soon as supplies arrive and continue to vaccinate as long as influenza is circulating

- 2 Communicate with patients
- Inform about VPDs at start of every visit
- Train staff to discuss vaccines during routine processes
- Promote vaccination among staff to set a good example

- 3 Enhance systems to facilitate vaccination
- Review accurate EMR vaccination record keeping
- Assess immunizations as part of vital signs
- Develop systematic processes for vaccinating every person with a vaccination need (eg, standing orders)

- 4 Get motivated
- Create a chart to track progress
- Provide ongoing feedback to staff on vaccination progress
- Reward successful results

EMR=electronic medical record; VPDs=vaccine-preventable diseases

Effectiveness of the 4 Pillars™ Practice Transformation Program in Increasing Uptake of Adult Vaccines¹

Posthoc analysis* of a trial to compare the effect of the 4 Pillars program on vaccination rates in patients aged 18–64 years with common high-risk medical conditions† (June 2013-January 2015; n=4737)



Uptake increased significantly (*P*<0.001) for Tdap, PPSV, and influenza vaccination

The overall uptake of recommended vaccines for those with high-risk conditions remained below national goals

Limitation: Population limited to greater Pittsburg region. Analysis compared intervention effect on adults with common high-risk conditions rather than demonstrate effectiveness against no program

^{*}Posthoc analysis of data from a randomized controlled cluster trial

[†]High-risk medical conditions included diabetes (n=1999), chronic lung disease (n=1682), chronic heart disease (n=658) or another high-risk condition (n=764) PPSV=pneumococcal polysaccharide vaccine; Tdap=tetanus, diphtheria, and acellular pertussis vaccine.

THANK YOU

Upcoming Webinar



Topic: Preparing for the 2022 Flu Season



Date/ Time: Thursday, June 16 at 2pm ET



Presenters: Amy Sitapati, M.D. and Kris Henderson, R.N., B.S.N., N.E.-B.C. of UC San Diego Health

Questions?





Submit your questions using the **Q&A feature** at the bottom of the screen